Brain cancer is scary, especially when it affects kids. A group of brain cancers, called pediatric high-grade gliomas, are both common and...
Rally-Funded Discovery: Blocking Brain Cancer’s Bosses
read more
Rally-Funded Discoveries
From Idea to Clinical Trial: How Dr. David Loeb’s Research Is Changing Childhood Cancer Treatment
Dr. David Loeb, M.D., Ph.D., from the Montefiore Einstein Comprehensive Cancer Center, has dedicated his career to finding better...
How Rally’s Early Support Helped Launch a Surgeon’s Mission to Defeat Childhood Cancer
When Eric Rellinger, M.D., was training to become a surgeon at Vanderbilt University Medical Center, he became fascinated by how cancer...
The Power of Seed Funding: Dr. Kevin Bunting’s Breakthroughs in Pediatric AML Research
When we first met Kevin Bunting, Ph.D., from Emory University, we saw a scientist with big ideas and bold goals. His work focused on...
Turning Data Into Hope: Rally’s Impact on Pediatric Brain Tumor Research
Since 2022, Rally Foundation for Childhood Cancer Research has played a key role in helping Adam Resnick, Ph.D., at Children’s Hospital of...
The Heart of Survivorship: How Rally Funding Helped Prevent Heart Failure in Childhood Cancer Survivors
For many kids who beat cancer, the battle does not end when treatment does. Years later, they can face new health challenges caused by the...
Fighting Osteosarcoma with a Bold Idea
When Lily Guenther, M.D., was just starting her career in childhood cancer research at Dana-Farber Cancer Institute, Rally Foundation for...
Helping Kids With Cancer Feel Better: How One Doctor’s Research Is Changing Lives
When kids go through cancer treatment, they often feel pain, nausea, anxiety and other tough symptoms and side effects. Lillian Sung,...
A Breakthrough for Down Syndrome and Leukemia
Kids with Down syndrome are 20 times more likely to get a type of blood cancer called acute lymphoblastic leukemia (ALL). Sadly, they also...
From Idea to Impact: How Rally’s Seed Funding Helped Dr. Christian Hurtz Make a Big Discovery
When kids get cancer, doctors and scientists work hard to find new and better treatments. But every big discovery starts with seed...
Cracking Neuroblastoma’s Code
Neuroblastoma is a hard-to-treat cancer that mostly affects kids. One of the biggest challenges is that some of the cancer cells learn to...
Blocking WDR5 to Fight Cancer
April Weissmiller, Ph.D., is a scientist who wants to help kids with cancer. Thanks to receiving grant funding from Rally Foundation...
Outsmarting RAS in Rhabdomyosarcoma Research
Did you know scientists can use viruses to fight cancer? It sounds wild, but it’s real. Eleanor Chen, M.D., Ph.D., is a researcher at the...
DFMO: A Neuroblastoma Breakthrough Sparked by Rally
At Rally Foundation, we believe that one discovery can change everything and sometimes, all it needs is a seed. From 2007 to 2015, we...
BWS and Liver Cancer Hope Ahead
Jennifer Kalish, M.D., Ph.D., and her team at Children’s Hospital of Philadelphia are studying a rare condition called Beckwith-Wiedemann...
Rally-Funded Discoveries
Rally-Funded Discovery: Protecting Hearts After Cancer
When kids go through cancer treatment, it’s not just the cancer doctors have to worry about. Sometimes, those powerful treatments can also hurt the heart. That’s where Eric Chow, M.D., a researcher at the Fred Hutchinson Cancer Center, comes in. Thanks to funding from Rally Foundation for Childhood Cancer Research, Dr. Chow and his team are working to spot heart problems early, before they become serious. Using Ultrasound to Watch the Heart Rally Foundation’s early funding helped Dr. Chow...
A Lifeline for Discovery: How Rally Kept Neuroblastoma Research Alive
When government research funding ran out, the lab of John O’Bryan, Ph.D., at the Medical University of South Carolina faced a tough moment. Their important work on pediatric neuroblastoma, an aggressive childhood cancer, was at risk of stopping. Then Rally Foundation for Childhood Cancer Research stepped in with a grant that changed everything. “Rally Foundation’s support was instrumental,” Dr. O’Bryan said. “It came at a critical time when we had no National Institutes of Health (NIH) funding...
How Rally Funding Helped Launch a Scientist’s Bold Ideas to Fight Brain Cancer
Christina von Roemeling, Ph.D., is on a mission to find better ways to treat brain tumors. When she was just starting her scientific career, Rally Foundation for Childhood Cancer Research gave her an important boost, a Postdoctoral and Clinical Research Fellow Grant in 2020. That support came during a tough time. Many research funders paused their work during the COVID-19 pandemic, but Rally kept going. This allowed Dr. von Roemeling to continue her work without delay. “The Rally Foundation...
Turning Early Funding Into Lifesaving Discoveries: Dr. Anthony Faber’s Neuroblastoma Breakthroughs
What if $100,000 could unlock $3.5 million and help bring new treatments to kids with cancer? That’s exactly what happened with Anthony Faber, Ph.D., a researcher at Virginia Commonwealth University, who received three grants from Rally Foundation for Childhood Cancer Research to fuel his groundbreaking work in neuroblastoma. Thanks to early seed funding from Rally Foundation: Dr. Faber discovered that venetoclax, a medicine that blocks a survival protein used by cancer cells, was effective...
Why Early Research Matters: Rally’s Role in Advancing Neuroblastoma Care
In 2020 and 2023, Smita Matkar, Ph.D., at the Children’s Hospital of Philadelphia (CHOP) received early research funding from Rally Foundation for Childhood Cancer Research. That support opened the door to study a hopeful idea. Could a type of targeted medicine, called an ALK inhibitor, help children with neuroblastoma, a cancer of the nervous system? Dr. Matkar studied a newer ALK inhibitor called lorlatinib. She found that it worked better than older FDA approved medicines like crizotinib....
A Bold Idea, Backed Early: Rally’s Role in Advancing Leukemia Research
In 2016, Kimberly Stegmaier, M.D., at the Dana-Farber Cancer Institute received early research funding from Rally Foundation for Childhood Cancer Research. That support allowed her team to explore a bold question. Could turning off two important enzymes, SHMT1 and SHMT2, slow down or even stop T-cell acute lymphoblastic leukemia, a type of childhood blood cancer that is very hard to treat when it returns? Dr. Stegmaier and her team tested a compound called RZ-2994 that blocks both SHMT1 and...